Prof. Anthony D.Ho

Medical Degrees

• Medical School (1968–1970) — University of Innsbruck, Austria
• Medical School (1970–1974) / Graduation (MD) — University of Heidelberg, Germany
• Internship — Medical Center, University of Heidelberg, Germany, 1974–1975

Fellowships & Special Training

• Training in Internal Medicine — Medical Center, University of Heidelberg, 1975–1980
• Training in Hematology & Oncology — Department of Medicine V, University of Heidelberg, 1980–1982
• Honorary Lecturer — Department of Hematology, Royal Free Hospital, London, UK, 1982–1983
• Licentiate Examination — Medical Council of Canada (LMCC), 1990
• Specialist Certification — Internal Medicine, Royal College of Physicians and Surgeons of Canada, 1990
• License Examination — Medical Board of California, USA, 1994

Certifications & Accreditations

• German Medical Council Registration
• Fellow — Royal College of Physicians and Surgeons of Canada
• Member — Heidelberg Academy of Sciences (since 2003)
• Member — Central Ethics Committee for Stem Cell Research, German Bundestag (since 2002)
• Member — German Society of Hematology and Medical Oncology (DGHO)
• Member — American Society of Hematology (ASH)

Major Conditions Treated

• Acute Myeloid Leukemia (AML)
• Acute Lymphoblastic Leukemia (ALL)
• Chronic Lymphocytic Leukemia (CLL)
• Hodgkin & Non-Hodgkin Lymphoma
• Multiple Myeloma
• Myelodysplastic Syndromes (MDS)
• Aplastic Anemia & Bone Marrow Failure
• Anemia & Iron Disorders
• Bleeding Disorders
• Blood Clotting Disorders (Thrombosis)

Sub-specialties

• Haematopoietic Stem Cell Transplantation: International pioneer in autologous, allogeneic, and umbilical cord blood transplantation — a leading Hematology specialist in Heidelberg, Germany.
• CAR-T Cell & Cellular Therapy: Initiator of the Heidelberg HD-CAR-1 trial for relapsed/refractory ALL and NHL — recognised among the best Hematology doctors in Germany.
• Translational Stem Cell Research: Specialist in adult and aged human haematopoietic stem cell biology and clinical translation.

Advanced Procedures & Treatments

• Autologous Peripheral Blood Stem Cell Transplantation
• Allogeneic Bone Marrow Transplantation
• Umbilical Cord Blood Transplantation
• CAR-T Cell Therapy (Investigational, HD-CAR-1)
• High-Dose Chemotherapy with Stem Cell Support
• Inotuzumab Ozogamicin Therapy for Relapsed B-Cell ALL
• Antibody Therapy & Targeted Therapy
• Molecular Diagnostics for Haematological Malignancies
• Bone Marrow Biopsy & Aspiration
• Therapeutic Apheresis & Stem Cell Mobilisation

Current Affiliation

• Heidelberg University Hospital (Universitätsklinikum Heidelberg), Heidelberg, Germany — Professor Emeritus, Department of Medicine V (Hematology, Oncology, Rheumatology); ongoing research and consultation activities (Present)

Past Affiliations

• Heidelberg University Hospital, Germany — Medical Director / Chair, Department of Medicine V (Hematology, Oncology, Rheumatology)
• University of California, San Diego (UCSD), USA — Tenured Professor, 1992–1998
• University of Ottawa, Canada — Full Professor, Department of Medicine, 1990–1992
• N.E. Ontario Regional Cancer Centre, Canada — Director of Research & Head of Clinical Trials, 1990–1992
• Heidelberg University, Germany — Professor of Medicine (Außerplanmäßig), 1989–1992
• Heidelberg University, Germany — Associate Professor, 1983–1989
• Royal Free Hospital, London, UK — Honorary Lecturer, Department of Hematology, 1982–1983

Academic & Research Roles

• Member — Central Ethics Committee for Stem Cell Research, German Bundestag (Berlin)
• Member — Heidelberg Academy of Sciences (since 2003)
• Principal Investigator — Heidelberg HD-CAR-1 trial (third-generation CAR-T cells in r/r ALL and NHL)
• Mentor and trainer of generations of haematologists at Heidelberg

Key Achievements

• 50+ years of clinical experience across Germany, UK, Canada, and the USA
• Performed Heidelberg's first autologous blood stem cell transplant in 1985 — patient remains in long-term remission
• Built Heidelberg into one of the world's largest stem cell transplantation centres (300+ transplants per year)
• Pioneered third-generation CAR-T cell trial (HD-CAR-1) for refractory ALL and NHL
• Department treats 7,000+ patients annually under his historical leadership

National & International Awards

• Member — Heidelberg Academy of Sciences (elected 2003)
• Multiple national and international honours for contributions to stem cell transplantation and translational hematology — Information about specific award names not fully publicly available.

Professional Memberships

• Heidelberg Academy of Sciences
• Royal College of Physicians and Surgeons of Canada (Fellow)
• German Society of Hematology and Medical Oncology (DGHO)
• American Society of Hematology (ASH)
• European Hematology Association (EHA)
• Central Ethics Committee for Stem Cell Research, German Bundestag

Published Papers (Selected)

• Heidelberg HD-CAR-1 Trial Investigators (incl. Ho AD). "Third-Generation Chimeric Antigen Receptor (CAR) T Cells in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) and Non-Hodgkin Lymphoma (NHL) — Results from the Heidelberg Trial 1 (HD-CAR-1)." Blood / ASH abstracts.
• Luskin MR, ..., Ho AD, et al. "Outcome after Inotuzumab Ozogamicin for Patients with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia and Extramedullary Disease." Multicentre study.
• Multiple peer-reviewed publications on aged versus young human hematopoiesis. Full citation list available via PubMed and ResearchGate (Heidelberg University).

Ongoing Research & Clinical Interests

• CAR-T cell therapy for refractory haematological malignancies
• Aged human haematopoietic stem cell biology
• Stem cell mobilisation and transplantation outcomes
• Translational research bridging molecular biology and clinical hematology
• Ethics of stem cell research and clinical translation

*Indicative estimates only. Actual costs subject to hospital pricing, case complexity, and insurance. Contact Cancer Rounds for a personalised quote.